Table 1 |
||||
|
Summary of studies on glucagon-like peptide-1 in hospitalized patients |
||||
|
Deane and colleagues [1] |
Mussig and colleagues [14] |
Sokos and colleagues [15] |
Meier and colleagues [16] |
|
|
|
||||
|
Patient population |
ICU, mechanically ventilated |
Post CABG |
Pre and post CABG |
Post major surgery |
|
Number of patients |
7 |
20 |
20 |
8 |
|
Male/female |
4/3 |
18/2 |
17/3 |
5/3 |
|
Diabetes mellitus |
No |
All |
5/20 |
All |
|
Nutrition |
Enteral feeding |
No parenteral feeding |
Allowed to eat |
Fasting |
|
Intervention |
GLP-1 at 1.2 pmol/kg/minute |
GLP-1 at 3.6 pmol/kg/minute |
GLP-1 at 1.5 pmol/kg/minute |
GLP-1 at 1.2 pmol/kg/minute |
|
Duration of intervention |
4.5 hours |
12 hours |
12 hours before CABG to 48 hours after CABG |
8 hours |
|
Control group |
Placebo (albumin) |
Insulin |
Placebo (saline) |
Placebo |
|
Results |
Significantly decreased AUC for glucose |
Glycemic control comparable with insulin-treated group |
Significantly decreased AUC for glucose |
Normoglycemia |
|
Side effects |
None |
None |
One episode of hypoglycemia |
None |
|
|
||||
|
AUC, area under the curve; CABG, coronary artery bypass grafting; GLP-1, glucagon-like peptide-1; ICU, intensive care unit. |
||||
|
Kovalaske and Gandhi Critical Care 2009 13:161 doi:10.1186/cc7913 |
||||